合計 50 件の最近のインサイダー取引記録が記録されています Cyclacel Pharmaceuticals, Inc. (CYCC), 内訳は 31 件の買い および 2 件の売り. インサイダー買い総額は $2.69M インサイダー売り総額は $42.86.
最近活動のある主要インサイダーには Suria Sukses Engineering Sdn Bhd, Tan Kok Hui, Ho Jien Shiung. インサイダー取引記録は、経営陣が株式の評価と将来の見通しをどう見ているかについての洞察を提供します.
インサイダー取引記録 — CYCC
| 日付 |
氏名 |
役職 |
取引種別 |
株数 |
平均価格 |
価値 |
保有株数 |
| 2025-04-29 |
Suria Sukses Engineering Sdn Bhd |
10 Percent Owner |
不明 |
- |
- |
- |
250,000 |
| 2025-04-29 |
Tan Kok Hui |
10 Percent Owner |
不明 |
- |
- |
- |
250,000 |
| 2025-04-29 |
Ho Jien Shiung |
10 Percent Owner |
不明 |
- |
- |
- |
250,000 |
| 2025-04-29 |
Ho Kee Wee |
10 Percent Owner |
不明 |
- |
- |
- |
250,000 |
| 2025-04-29 |
Tan Kok Hui |
Officer |
不明 |
- |
- |
- |
- |
| 2025-04-29 |
Suria Sukses Engineering Sdn Bhd |
Officer |
不明 |
- |
- |
- |
- |
| 2025-04-29 |
Ho Jien Shiung |
Officer |
不明 |
- |
- |
- |
- |
| 2025-04-29 |
Ho Kee Wee |
Officer |
不明 |
- |
- |
- |
- |
| 2025-04-02 |
Nair Krishnan Satis Waran |
Director |
不明 |
- |
- |
- |
- |
| 2025-04-02 |
Laurduraj Inigo Angel |
Director |
不明 |
- |
- |
- |
- |
| 2025-02-26 |
Natan David |
Director |
RSU 付与(制限付株式) |
700,000 |
$0.33 |
$231K |
700,000 |
| 2025-02-26 |
Kiu Cu Seng |
CFO and Secretary |
不明 |
- |
- |
- |
- |
| 2025-02-26 |
Doris Wong Sing Ee |
10 Percent Owner, Officer: Chief Executive Officer |
不明 |
- |
- |
- |
194,628,820 |
| 2025-02-26 |
Chong Kwang Fock |
Director |
不明 |
- |
- |
- |
- |
| 2025-02-26 |
Lazar David E. |
10 Percent Owner, Officer: Interim CEO |
オプション行使(売却) |
1,000,000 |
- |
- |
- |
| 2025-02-26 |
Ben-tzvi Avraham |
Director |
RSU 付与(制限付株式) |
700,000 |
$0.33 |
$231K |
700,000 |
| 2025-02-06 |
Lazar David E. |
10 Percent Owner, Officer: Interim CEO |
RSU 付与(制限付株式) |
2,100,000 |
- |
- |
2,100,000 |
| 2025-01-05 |
Ben-tzvi Avraham |
Director |
不明 |
- |
- |
- |
- |
| 2025-01-02 |
Natan David |
Director |
不明 |
- |
- |
- |
- |
| 2025-01-02 |
Natan David |
Director |
RSU 付与(制限付株式) |
100,000 |
- |
- |
100,000 |
| 2025-01-02 |
Lazar David E. |
Chief Executive Officer |
不明 |
2,650,000 |
- |
- |
- |
| 2024-01-29 |
Schwartz Brian |
Interim Chief Medical Officer |
RSU 付与(制限付株式) |
12,500 |
$2.28 |
$28.5K |
12,500 |
| 2023-12-21 |
Rombotis Spiro George |
President and CEO |
情報に基づく買い |
6,070 |
$3.19 |
$19.36K |
6,070 |
| 2023-12-21 |
Mcbarron Paul |
See Remarks |
情報に基づく買い |
1,886 |
$3.19 |
$6.02K |
1,886 |
| 2023-06-30 |
Barker Sam L |
Director |
RSU 付与(制限付株式) |
21,219 |
- |
- |
40,415 |
| 2023-06-30 |
Henney Christopher S |
Director |
RSU 付与(制限付株式) |
21,219 |
- |
- |
39,415 |
| 2023-06-30 |
Rombotis Spiro George |
President and CEO |
RSU 付与(制限付株式) |
110,000 |
$0.59 |
$64.8K |
110,000 |
| 2023-06-30 |
Mcbarron Paul |
See Remarks |
RSU 付与(制限付株式) |
70,200 |
$0.59 |
$41.35K |
70,200 |
| 2023-06-30 |
Schwartz Brian |
Director |
RSU 付与(制限付株式) |
21,219 |
- |
- |
40,602 |
| 2023-06-30 |
Spiegel Robert J. |
Director |
RSU 付与(制限付株式) |
21,219 |
- |
- |
39,415 |
| 2023-06-30 |
Walker Karin L |
Director |
RSU 付与(制限付株式) |
21,219 |
- |
- |
40,602 |
| 2023-06-30 |
Kirschbaum Mark |
Chief Medical Officer |
RSU 付与(制限付株式) |
70,200 |
$0.59 |
$41.35K |
70,200 |
| 2023-06-30 |
Ferguson Kenneth M. |
Director |
RSU 付与(制限付株式) |
42,438 |
$0.59 |
$25K |
42,438 |
| 2023-01-31 |
Rombotis Spiro George |
President and CEO |
RSU 付与(制限付株式) |
57,600 |
- |
- |
62,588 |
| 2023-01-31 |
Mcbarron Paul |
See Remarks |
RSU 付与(制限付株式) |
31,200 |
- |
- |
31,492 |
| 2023-01-31 |
Kirschbaum Mark |
Chief Medical Officer |
RSU 付与(制限付株式) |
31,200 |
- |
- |
31,200 |
| 2022-06-14 |
Barker Sam L |
Director |
RSU 付与(制限付株式) |
15,822 |
- |
- |
19,196 |
| 2022-06-14 |
Henney Christopher S |
Director |
RSU 付与(制限付株式) |
15,822 |
- |
- |
18,196 |
| 2022-06-14 |
Schwartz Brian |
Director |
RSU 付与(制限付株式) |
15,822 |
- |
- |
19,383 |
| 2022-06-14 |
Sems Lloyd |
Director |
RSU 付与(制限付株式) |
15,822 |
- |
- |
18,196 |
| 2022-06-14 |
Spiegel Robert J. |
Director |
RSU 付与(制限付株式) |
31,645 |
- |
- |
31,645 |
| 2022-06-14 |
Walker Karin L |
Director |
RSU 付与(制限付株式) |
31,645 |
- |
- |
31,645 |
| 2022-06-14 |
Ferguson Kenneth M. |
Director |
不明 |
- |
- |
- |
- |
| 2022-06-14 |
Ferguson Kenneth M. |
Director |
RSU 付与(制限付株式) |
27,733 |
- |
- |
27,733 |
| 2022-06-14 |
Ferguson Kenneth M. |
Director |
RSU 付与(制限付株式) |
23,733 |
- |
- |
23,733 |
| 2021-12-13 |
Rombotis Spiro George |
President and CEO |
RSU 付与(制限付株式) |
190,000 |
$3.45 |
$655.5K |
190,000 |
| 2021-12-13 |
Mcbarron Paul |
See Remarks |
RSU 付与(制限付株式) |
100,000 |
$3.45 |
$345K |
100,000 |
| 2021-12-13 |
Kirschbaum Mark |
Chief Medical Officer |
RSU 付与(制限付株式) |
100,000 |
$3.45 |
$345K |
100,000 |
| 2021-12-13 |
Rombotis Spiro George |
President and CEO |
RSU 付与(制限付株式) |
190,000 |
$3.45 |
$655.5K |
190,000 |
| 2021-11-30 |
Barker Sam L |
Director |
情報に基づく売り |
12 |
$3.57 |
$42.86 |
3,374 |
■ 情報付き — 公開市場取引(最も重要)
■ 情報なし(買い) — 報酬・オプション行使・転換
■ 情報なし(売り) — 源泉徴収・付与売却
■ 中立 — 贈与・信託・失効